MFDS Approves Rare Liver Disease Treatment 'Livdelzi Capsule'
3 Articles
3 Articles
(Seoul = Yonhap News) Reporter Park Sang-hyun = The Ministry of Food and Drug Safety [announced] 'Livdelzi Capsule' (celadelfarisin dihydrate), an imported rare drug used to treat primary biliary cholangitis...
The Ministry of Food and Drug Safety announced on the 20th that it has approved 'Livdelzi Capsules (active ingredient: seladelparisin dihydrate),' a treatment for primary biliary cholangitis (PBC) from Gilead Sciences of the United States. Primary biliary cholangitis is an autoimmune disease in which the immune system attacks the bile ducts within the liver, causing inflammation and damage. If bile is not properly drained, it accumulates in the …
The Ministry of Food and Drug Safety [referred to] adult patients with primary biliary cholangitis who have no tolerance or insufficient response to ursodeoxycholic acid (UDCA).
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
